The primary objectives of Component 8 are to test key aspects of our unique theoretical model focused on neuroimmune mechanisms contributing to methamphetamine (MA) induced neuropsychiatric impairments, and to test our central hypothesis that immunomodulatory agents can promote brain healing and neuropsychiatric recovery following chronic MA dependence by reducing neuroinflammation and by addressing hyper-reactivity to neuroantigen.
Specific Aim 1 - In humans, to identify peripheral immune factors most significantly impacted by chronic MA dependence and which correspond with MA induced neuropsychiatric impairments. Peripheral blood mononuclear cells (PBMCs) will be collected from humans who are non-dependent, actively using, and in early remission from MA dependence. Gene expression array analyses will be conducted to identify immune factors that are differentially expressed across groups and which correspond with cognitive and psychiatric symptom measures. Results will be compared with similar gene expression data collected from MA and saline exposed mice in Component 9.
Specific Aim 2 - In humans, to fully characterize the effects of chronic MA dependence on peripheral immune cell function as measured by in vitro reactivity to neuroantigens and other antigens, and to characterize the relationship between MA induced neuropsychiatric impairment and altered peripheral immunoreactivity. PBMCs will be collected from humans who are non-dependent, actively using, and in early remission from MA dependence followed by stimulation with neuroantigens and other antigens, immune factor detection assays and cell proliferation experiments.
Specific Aim 3 - In mice, to evaluate the therapeutic activity of one novel immunotherapy, [multiple antigenic (Ag) peptide (MAP)], in reducing MA induced neuropsychiatric impairments, central nervous system (CNS) injury, neuroinflammation, and trafficking of neuroantigen-reactive immune cells from the periphery to the CNS. Following saline versus repeated MA exposure, mice will be treated with MAP versus vehicle followed by memory and anxiety tests and brain and spleen collection and analysis.

Public Health Relevance

There are no FDA-approved pharmacotherapies for MA addiction, and relapse rates associated with substance abuse treatment programs remain unacceptably high. As an alternative to traditional neurotransmitter based approaches, our proposed research offers immunomodulatory agents as a potential new strategy for the treatment of MA induced CNS injury and neuropsychiatric impairment. If successful, this new direction would be a major breakthrough for addiction medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
2P50DA018165-06A1
Application #
8355339
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-06-30
Support Year
6
Fiscal Year
2012
Total Cost
$178,975
Indirect Cost
$36,931
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Szumlinski, Karen K; Lominac, Kevin D; Campbell, Rianne R et al. (2016) Methamphetamine Addiction Vulnerability: The Glutamate, the Bad, and the Ugly. Biol Psychiatry :
Li, Minghua; Underhill, Suzanne M; Reed, Cheryl et al. (2016) Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology :
Lominac, Kevin D; Quadir, Sema G; Barrett, Hannah M et al. (2016) Prefrontal glutamate correlates of methamphetamine sensitization and preference. Eur J Neurosci 43:689-702
Loftis, Jennifer M; Lim, Miranda M (2016) Sleep disturbance in substance use disorders and comorbid chronic viral infections. Addiction 111:1093-4
Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah et al. (2016) Everyday problems with executive dysfunction and impulsivity in adults recovering from methamphetamine addiction. Addict Disord Their Treat 15:1-5
Kim, Hyunjee; Hartung, Daniel M; Jacob, Reside L et al. (2016) The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. Psychiatr Serv 67:397-404
Janowsky, Aaron; Tosh, Dilip K; Eshleman, Amy J et al. (2016) Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine. J Pharmacol Exp Ther 357:24-35
Greenberg, G D; Huang, L C; Spence, S E et al. (2016) Nest building is a novel method for indexing severity of alcohol withdrawal in mice. Behav Brain Res 302:182-90
Zou, Mu-Fa; Keck, Thomas M; Kumar, Vivek et al. (2016) Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. J Med Chem 59:2973-88
Abraham, Antony D; Neve, Kim A; Lattal, K Matthew (2016) Effects of D1 receptor knockout on fear and reward learning. Neurobiol Learn Mem 133:265-73

Showing the most recent 10 out of 120 publications